Clinical Trials
1
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
1
100.0%
No approval data available
- A Nature study presents the first genomic analysis of eight Myotis bat species, linking longer lifespans to stronger immune defense and cancer-suppressing gene activity. - Cells from the little brown bat responded to lethal chemical damage by activating cell-death genes rather than DNA repair, mirroring the elephant's anti-cancer strategy. - Researchers found far more overlap than expected by chance between genes associated with bat longevity and genes involved in bat-virus interactions. - Myotis bats show unusual enrichment of genes interacting with DNA viruses such as herpesviruses, a pattern opposite to humans and other primates.
- Researchers at University of Pittsburgh and Penn State developed a novel "trans-amplifying" mRNA vaccine platform that requires 40 times less mRNA than conventional vaccines while maintaining robust immune responses. - The innovative approach separates mRNA into two fragments, allowing the replicase sequence to be produced in advance and significantly reducing vaccine development time and production costs. - The vaccine uses a consensus spike protein design that demonstrated broad protection against multiple SARS-CoV-2 variants in mouse studies, potentially eliminating the need for frequent updates. - The platform shows promise for application to other rapidly evolving RNA viruses with pandemic potential, including H5N1 avian influenza.
